News

NeuroBo Pharmaceuticals Advances Phase 2a Trial for DA-1241

NeuroBo Pharmaceuticals Advances Phase 2a Trial for DA-1241

NeuroBo Pharmaceuticals Advances Phase 2a Trial for DA-1241

NeuroBo Pharmaceuticals, Inc. is making significant strides in its clinical development efforts. This clinical-stage biotechnology company has recently announced a major milestone with the completion of the last patient’s visit in its two-part, Phase 2a clinical trial, which evaluates the efficacy and safety of DA-1241. This investigational drug targets metabolic dysfunction-associated steatohepatitis (MASH) through a novel mechanism as a G-Protein-Coupled Receptor 119 (GPR119) agonist.

DA-1241 and Its Clinical Significance

The completion of patient dosing in this trial is particularly significant as it brings NeuroBo one step closer to a topline data readout expected soon. The data will provide insights into the drug’s comparative efficacy against both placebo and in combination with sitagliptin, a DPP-4 inhibitor, which may enhance therapeutic outcomes.

Understanding the Mechanism of DA-1241

DA-1241’s mechanism involves the stimulation of GPR119, leading to the release of crucial gut peptides such as GLP-1, GIP, and PYY. These peptides are critical for improving glucose metabolism and lipid profiles, potentially offering a new solution for those facing challenges related to MASH. Previous Phase 1 studies suggested that DA-1241 is well tolerated, further reinforcing its promise as a therapeutic option.

Design of the Phase 2a Clinical Trial

The Phase 2a trial is structured into two separate components, both designed as multicenter, randomized, double-blind, placebo-controlled studies. Each part spans 16 weeks and includes a diverse group of patients diagnosed with presumed MASH. Out of 109 randomized patients, 95 completed the treatment regimen, which included DA-1241 administered at varying doses depending on the trial part.

Endpoints and Expectations

The primary endpoint of both parts is to assess the change in alanine transaminase (ALT) levels after 16 weeks of treatment. Secondary endpoints delve into cholesterol profiles, triglyceride levels, and other metabolic markers, raising hopes for comprehensive data supporting DA-1241's efficacy and safety.

About NeuroBo Pharmaceuticals

Founded with a dedication to transforming cardiometabolic diseases, NeuroBo Pharmaceuticals is also working on DA-1726, another innovative drug targeting obesity. DA-1241 is pivotal as it approaches its final evaluation in the clinical pathway for MASH treatment.

In addition to its therapeutic targets, NeuroBo's commitment extends to demonstrating the potential benefits of DA-1241 in various preclinical studies. These studies have indicated that it not only improves liver health but also positively affects glucose control and lipid metabolism.

Looking Ahead

With the completion of key clinical milestones for DA-1241, NeuroBo Pharmaceuticals is poised to release critical data that may reshape the landscape of treating MASH. Stakeholders eagerly await the trial results that could pave the way for possible future approvals and therapeutic approaches in managing this complex metabolic disorder.

Frequently Asked Questions

What is the purpose of the Phase 2a trial for DA-1241?

The Phase 2a trial aims to evaluate the efficacy and safety of DA-1241 in patients with metabolic dysfunction-associated steatohepatitis (MASH).

How many patients were involved in the trial?

a total of 109 patients were randomized, with 95 completing the dosing for the two-part clinical trial.

What outcomes are being monitored in this trial?

The primary outcome involves measuring changes in alanine transaminase (ALT) levels, while secondary outcomes include cholesterol levels and other metabolic indicators.

Who is the leading figure at NeuroBo Pharmaceuticals?

Hyung Heon Kim serves as the President and Chief Executive Officer of NeuroBo Pharmaceuticals, overseeing the company's strategic direction.

Where can I find more information about the clinical trial?

More details can be accessed through clinical trial registries or NeuroBo's official communications.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

JLL’s Facility Management Push Gets a Useful Nod From Frost

Updated Category News Views 27

A Building Breaks Down Long Before the Earnings Call Notices Facility management is the sort of business that gets ignored until an airport system fails, a data-center cooling unit balks, or a workforce cannot use the building it was told to return to. That is why Frost & Sullivan’s 2026 recognition of JLL deserves more than the usual award-season shrug. It points to an...

Continue Reading
Kyndryl's Gartner Sweep Raises the Execution Bar Again

Updated Category News Views 95

A workplace help-desk ticket may sound dull as drywall, but at a giant enterprise it can become a very expensive little failure. That is why Kyndryl's latest Gartner recognition deserves more than the usual corporate backslapping. The company was named a Leader in Gartner's 2026 Magic Quadrant for Outsourced Digital Workplace Services for a third consecutive year, and...

Continue Reading
Zunyi’s History Tour Carries China’s Story Overseas

Updated Category News Views 196

China’s national story does not travel overseas by accident; it gets carried by visitors, monuments, rail lines, rivers and carefully chosen questions. The Zunyi News and Media Center report follows Tayyab, a Pakistani PhD student in aerospace engineering at Peking University, as he heads from Beijing to Zunyi, Guizhou, carrying a copy of Edgar Snow’s Red Star Over...

Continue Reading
Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 118

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading
Emaar's Huspy Deal Brings Financing Into Home Sales

Updated Category News Views 51

Mortgage paperwork is nobody’s idea of luxury, yet it can wreck a property sale faster than a bad floor plan. Emaar Properties has partnered with Dubai-based Huspy to give its customers access to mortgage advice and financing comparisons from more than 20 UAE banks. It is not a flashy tower launch or a headline-grabbing land purchase. Frankly, that is why investors...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 81

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
A €18 Million Mecca Chandelier Tests Austrian Craft

Updated Category News Views 212

Scale Is Easy to Boast About, Delivery Is Not A 34.1-metre chandelier hanging in Mecca is the sort of job that makes ordinary project talk sound downright silly. Lights of Vienna says it designed, built, tested, shipped and installed this monster for the Grand Mosque's Shamiya area, with a contract value of roughly €18 million. That is a serious piece of work for a...

Continue Reading
Pressure Injury Care Needs More Than Awareness Alone

Updated Category News Views 52

Wet skin does not care how polished the awareness campaign looks. That is the uncomfortable truth sitting underneath Worldwide Pressure Injury Prevention Day, the annual observance held on the third Thursday of November. Pressure injuries remain a stubborn problem across healthcare facilities and home care settings because prevention is not one tidy action; it is a chain...

Continue Reading
Humanoid Robots Need Results Before 2035 Hype Peaks

Updated Category News Views 245

A robot climbing stairs is neat; a robot finishing Tuesday’s shift is the investment case. The latest humanoid robotics forecast puts the global market at $3.07 billion in 2026, up from $2.26 billion in 2025, and projects $47.49 billion by 2035. That is a 35.59% compound annual growth rate, the kind of number that makes investors sit up straight. It also demands a...

Continue Reading
Star Catcher Powers a Public-Interest Space Bet Ahead

Updated Category News Views 56

A satellite’s battery budget is a rotten place for humanitarian priorities to die. Common Space and Star Catcher are trying to remove that bottleneck through a partnership that is easy to like on principle and still deserves a clear-eyed look on execution. Common Space, a nonprofit developing an independent, community-governed high-resolution satellite constellation,...

Continue Reading

Top 5 Most Recently Viewed Articles

Science Applications Intl's Earnings Preview: Key Insights Ahead

Updated Category News Views 170

Understanding Science Applications Intl's Earnings Preview Science Applications Intl (NYSE: SAIC) is gearing up for its quarterly earnings announcement. Investors are eager to see how the company performs and whether it meets analysts' expectations. What to Anticipate Analysts project Science Applications Intl will report an earnings per share (EPS) of $2.11, which could...

Continue Reading
Innovative Aerogels Paving the Path for Water Harvesting Solutions

Updated Category News Views 285

Introduction to Atmospheric Water Harvesting The world faces an alarming freshwater crisis, with projections indicating that vast segments of the population are at risk of water scarcity. In response, researchers have innovatively turned to atmospheric water harvesting, particularly highlighting the advancements made by the National University of Singapore (NUS). They...

Continue Reading
Class Action Lawsuit Alert for Tronox Holdings Plc Investors

Updated Category News Views 131

Insights into the Tronox Holdings Class Action Lawsuit Investors in Tronox Holdings Plc (NYSE: TROX) should be aware of a class action lawsuit initiated against the company. This legal action centers around allegations of potential securities fraud and improper business practices by Tronox and some of its leadership. The firm Pomerantz LLP, known for its expertise in...

Continue Reading
Rapport Therapeutics Set to Showcase Innovations in Healthcare

Updated Category News Views 128

Rapport Therapeutics to Attend Major Investor Conferences BOSTON and SAN DIEGO — Rapport Therapeutics, Inc. (Nasdaq: RAPP), a biotechnology firm at the forefront of developing small molecule precision medicines targeting neurological and psychiatric disorders, has expressed its excitement about participating in two notable investor conferences soon. Details of Upcoming...

Continue Reading
Northwestern Mutual Achieves Unmatched Financial Strength Ratings

Updated Category News Views 353

Northwestern Mutual Achieves Elite Financial Ratings for 35 Years For an impressive 35 years, Northwestern Mutual has consistently earned top financial strength ratings from the nation's leading rating agencies. This recognition underscores the company’s commitment to maintaining a robust financial foundation, which plays a crucial role in their ability to serve clients...

Continue Reading